Vivoryon Therapeutics N.V.
Edit

Vivoryon Therapeutics N.V.

https://www.vivoryon.com/
Last activity: 04.03.2024
Active
Categories: BuildingDevelopmentDrugHealthTechWebsite
We are passionate about creating small molecule medications by building on our in-depth understanding of pathologic pathways with a single goal in mind: improving the lives of all those who are affected by severe diseases.
Followers
242
Followers
898
Mentions
11
Location: Germany, Saxony-Anhalt, Halle (Saale)
Employees: 11-50
Founded date: 1997

Investors 3

Mentions in press and media 11

DateTitleDescription
31.07.2022Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O...Safety data from 181 patients show no on-target toxicity and no clinical signs of ARIA Therapeutic dose of 600 mg varoglutamstat given twice daily selected by the Data Safety Monitoring Board is known to result in a target occupancy of near...
31.07.2022Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022Data underscore the unique potential of Vivoryon's N3pE-focused strategy in mono- and combination therapy settings in AD Combination treatment of aducanumab and varoglutamstat achieves additive effect on Abeta pathology, indicating feasibil...
21.09.2021Vivoryon Therapeutics N : PresentationHALF YEAR 2020 RESULTS WEBCAST AND CONFERENCE CALL September 21, 2021 |Vivoryon Therapeutics N.V. IMPORTANT NOTICE AND DISCLAIMER This Presentation has been prepared and issued by Vivoryon Therapeutics N.V. (the "Company") and has...
25.06.2021PRESS RELEASE : Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Financial Results for the First Quarter of 2021 and Provides Corporate UpdateDGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Quarter Results/Quarterly / Interim Statement Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Financial Results for the First Quarter of 2021 and Provides Corporate Update 202...
25.06.2021Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Financial Results for the First Quarter of 2021 and Provides Corporate UpdateDGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Quarter Results/Quarterly / Interim Statement Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Financial Results for the First Quarter of 2021 and Provides Corporate Update 25....
17.05.2021VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Notice of its Annual General Meeting of Shareholders to be Held on June 28, 2021DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): AGM/EGM Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Notice of its Annual General Meeting of Shareholders to be Held on June 28, 2021 17.05.2021 / 07:00 The issuer is solel...
17.05.2021VIVORYON THERAPEUTICS N.V. PRESS RELEASE : Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Notice of its Annual General Meeting of Shareholders to be Held on June 28, 2021DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): AGM/EGM Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Notice of its Annual General Meeting of Shareholders to be Held on June 28, 2021 2021-05-17 / 07:00 The issuer is solel...
30.04.2021Vivoryon Therapeutics N : Board Report and Financial Statements for the Financial Year ended December 31, 2020 (english)Vivoryon Therapeutics N.V. Amsterdam, The Netherlands Annual Report 2020 Precision Intervention Medicines - Pioneering Innovation FORWARD-LOOKING STATEMENTS ......................................................................................
27.08.2020VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics : Interim Financial Statements 30 June 2020 (HGB) (english)Interim Financial Statements as at 30 June 2020 and Interim management report of Vivoryon Therapeutics AG (HGB) Balance sheet Income statement Cash flow statement Statement of changes in equity Condensed notes to the interim Financial state...
26.06.2020VIVORYON THERAPEUTICS N.V. Vivoryon Therapeutics AG: Vivoryon Therapeutics Provides Update on US and EU Alzheimer's Clinical Trial Program with PQ912DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous Vivoryon Therapeutics AG: Vivoryon Therapeutics Provides Update on US and EU Alzheimer's Clinical Trial Program with PQ912 26.06.2020 / 07:00 The issuer is solely responsible ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In